CompanyGraph
Qinghai Spring Medicinal Resources Co., Ltd.
600381 · SSE · China
verygrass.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.43BCNY362.94M · vs all stocks (USD)
Revenue (TTM)
277.65MCNY41.46M · vs all stocks (USD)
Profit Margin
-26.92%Beta
0.6990xvs all stocks
52-Week Change
-18.34%vs all stocks
Market Capitalization
2.43BCNY362.94M · vs all stocks (USD)
Enterprise Value
2.13BCNY317.65M · vs all stocks (USD)
Forward P/E
4.70xPrice to Sales (TTM)
8.75xPrice to Book (MRQ)
2.42xEnterprise to Revenue
7.66xEnterprise to EBITDA
-37.90xGross Margin
56.94%Profit Margin
-26.92%Operating Margin
-194.12%Return on Assets (TTM)
-4.24%Return on Equity (TTM)
-7.48%Revenue (TTM)
277.65MCNY41.46M · vs all stocks (USD)
Revenue per Share (TTM)
0.5500CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-63.00%Gross Profit (TTM)
80.23MCNY11.98M · vs all stocks (USD)
EBITDA (TTM)
39.20MCNY5.85M · vs all stocks (USD)
Net Income (TTM)
-74.73MCNY-11.16M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-62.97%Operating Cash Flow (TTM)
11.61MCNY1.73M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
20.51MCNY3.06M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
4.37MCNYFY2025 · Dec 31, 2025Revenue
343.42MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
201.01MCNYFY2025 · Dec 31, 2025Gross Profit
142.41MCNYFY2025 · Dec 31, 2025Operating Income
1.07MCNY159.95K · vs all stocks (USD)
Pre-tax Income
-25.02MCNYFY2025 · Dec 31, 2025Income Tax Expense
11.06MCNYFY2025 · Dec 31, 2025Net Income
-36.08MCNYFY2025 · Dec 31, 2025EBIT
-24.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
39.20MCNYFY2025 · Dec 31, 2025Research & Development
10.57MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
87.57MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.02MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
214.43KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
533.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
533.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-36.08MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.24MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-11.35MCNYFY2025 · Dec 31, 2025Free Cash Flow
-17.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
163.88MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-36.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-7.58MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
18.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
13.68MCNYFY2025 · Dec 31, 2025Capital Expenditures
-6.52MCNYFY2025 · Dec 31, 2025Purchase of Investments
-88.00MCNYFY2025 · Dec 31, 2025Sale of Investments
88.05MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-6.46MCNYFY2025 · Dec 31, 2025Other Financing Charges
-9.93MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-9.93MCNYFY2025 · Dec 31, 2025Shares Outstanding
587.06MSharesUpdated Sep 21, 2026Float Shares
326.98MSharesUpdated Sep 21, 2026% Held by Insiders
47.39%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
248.68MCNY37.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4340CNYUpdated Sep 21, 2026Total Debt (MRQ)
1.58MCNY236.36K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0016xCurrent Ratio (MRQ)
18.69xBook Value per Share (MRQ)
1.71CNYUpdated Sep 21, 2026Total Assets
1.04BCNY155.97M · vs all stocks (USD)
Total Current Assets
651.30MCNYFY2025 · Dec 31, 2025Total Liabilities
44.87MCNYFY2025 · Dec 31, 2025Total Non-current Assets
393.17MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
744.67KCNYFY2025 · Dec 31, 2025Total Current Liabilities
44.12MCNYFY2025 · Dec 31, 2025Cash
163.74MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.63MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
166.37MCNYFY2025 · Dec 31, 2025Other Short-term Investments
739.32KCNYFY2025 · Dec 31, 2025Accounts Receivable
51.79MCNYFY2025 · Dec 31, 2025Inventory
159.29MCNYFY2025 · Dec 31, 2025Accounts Payable
4.13MCNYFY2025 · Dec 31, 2025Short-term Debt
2.56MCNYFY2025 · Dec 31, 2025Other Current Liabilities
309.91KCNYFY2025 · Dec 31, 2025Long-term Debt
407.27KCNYFY2025 · Dec 31, 2025Common Stock (Book)
587.06MCNYFY2025 · Dec 31, 2025Retained Earnings
97.96MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
999.61MCNY149.27M · vs all stocks (USD)
Treasury Stock
33.75MCNYFY2025 · Dec 31, 202552-Week Low
2.48CNYUpdated Sep 21, 202652-Week High
5.90CNYUpdated Sep 21, 202652-Week Change
-18.34%vs all stocks
Beta
0.6990xvs all stocks
50-Day MA
4.17CNYUpdated Sep 21, 2026200-Day MA
4.01CNYUpdated Sep 21, 2026Avg 10-Day Volume
5.10MSharesUpdated Sep 21, 2026Avg 30-Day Volume
6.65MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.1300CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: -0.27
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule